Clinical trials: Squamous Cell Lung Carcinoma
Non-Small Cell Lung Cancer, Melanoma
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
- Trial name
- NCT02974725
- Testing
- LXH254, LTT462, Trametinib
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897533
- Testing
- gene mapping, polymorphism analysis, diagnostic laboratory biomarker analysis
- Volunteers
- 137 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor
- Trial name
- NCT05099549
- Testing
- AFM24, SNK01
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- NKGen Biotech, Inc.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Lung Cancer, Breast Cancer
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium [177Lu]…
- Conditions
- Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumors
- Trial name
- NCT07274852
- Testing
- Lutetium [177Lu] BL-ARC001
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Lung Cancer, Malignant Mesothelioma
Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease
RATIONALE: Diagnostic procedures, such as optical coherence tomography, may help find and diagnose lung cancer or precancerous cells.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Nonmalignant Neoplasm
- Trial name
- NCT00733252
- Testing
- bronchoscopic and lung imaging studies, diagnostic bronchoscopy, histopathologic examination
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy…
- Conditions
- Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation
- Trial name
- KEAPSAKE (NCT04265534)
- Testing
- Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy
- Where
- 102 sites in United States
- Volunteers
- 40 people
- Sponsor
- Calithera Biosciences, Inc
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III…
- Trial name
- NCT07122687
- Testing
- Pemetrexed, Cisplatin, IBI363
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Carcinoma, Non-Small-Cell Lung
MYLUNG Consortium Part 3: Observational Study
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced…
- Trial name
- MYLUNG (NCT05885698)
- Where
- 17 sites in United States
- Volunteers
- 7,500 people
- Sponsor
- US Oncology Research
Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
This phase II trial studies how well MLN4924 (pevonedistat), carboplatin, and paclitaxel work in treating patients with stage IIIB or IV non-small cell lung cancer.
- Conditions
- Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03965689
- Testing
- Carboplatin, Paclitaxel, Pevonedistat
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
- Conditions
- Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC)
- Trial name
- DESCENT-1 (NCT06885424)
- Testing
- No additional intervention administered in this long term follow-up study
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- A2 Biotherapeutics Inc.
NSCLC (Advanced Non-small Cell Lung Cancer)
A Retrospective Real-World Study Based on RATIONALE-307
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in…
- Trial name
- NCT07478809
- Testing
- No intervention
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Lung Cancer
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00326599
- Testing
- carboplatin, cediranib maleate, gemcitabine hydrochloride
- Where
- 154 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Lung Carcinoma
TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
This is a non-randomized, open label, sequentially enrolling phase II study with a Simon two-step enrollment design to evaluate the activity of TAS-102 in previously treated unresectable or metastatic squamous non-small cell…
- Trial name
- NCT02920476
- Testing
- TAS-102
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Florida
Carcinoma, Non-Small-Cell Lung
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV
This study wants to determine the activity of a first-line treatment related to Thymidylate Synthetase (TS) Expression. Patients with the diagnosis of non-squamous advanced Non-Small-Cell Lung-Cancer (Stage IV) and without…
- Trial name
- SELECT-A (NCT01674738)
- Testing
- Pemetrexed, Cisplatin, Bevacizumab
- Sponsor
- Aktion Bronchialkarzinom e.V.
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02520778
- Testing
- Navitoclax, Osimertinib
- Where
- 18 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity
This study evaluates gut microbiome and functional status as modifiable biomarkers in predicting immunotherapy response and toxicity in patients with stage IV non-squamous non-small cell lung cancer receiving pembrolizumab alone…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04954885
- Testing
- Biospecimen Collection, Physical Performance Testing, Questionnaire Administration
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.